Spyre Therapeutics, Inc.
SYRE· Nasdaq
SYRESpyre Therapeutics, Inc.
Filed May 9, 2017 · 10-Q · 39 days after period end · 0001564590-17-009615
| Metric | Q1 2017 | Q1 2016 | Q1 2015 |
|---|---|---|---|
| Revenue | $982.00K | — | — |
| Net Income | -$6.25M | -$4.55M | -$2.47M |
| EPS Diluted | -$0.47 | -$7.10 | -$4.71 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spyre Therapeutics, Inc. · CIK 1636282 · Engraved from SEC EDGAR
ended Mar 31, 2017 · filed May 9, 2017 · 39 d after period end
